Sigyn Therapeutics, Inc.
SIGY
$2.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -40.76% | 27.48% | 35.18% | -23.42% | 40.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.20% | -22.11% | -13.32% | -33.35% | 25.78% |
| Operating Income | 52.20% | 22.11% | 13.32% | 33.35% | -25.78% |
| Income Before Tax | 51.67% | -68.27% | 11.81% | 55.55% | -32.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.67% | -68.27% | 11.81% | 55.55% | -32.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.67% | -68.27% | 11.81% | 55.55% | -32.15% |
| EBIT | 52.20% | 22.11% | 13.32% | 33.35% | -25.78% |
| EBITDA | 52.11% | 21.93% | 13.32% | 33.20% | -25.89% |
| EPS Basic | 61.80% | -29.79% | 32.41% | 65.12% | -15.19% |
| Normalized Basic EPS | 61.80% | -28.23% | 32.41% | 71.18% | -15.18% |
| EPS Diluted | 61.80% | -29.14% | 32.26% | 64.73% | -15.05% |
| Normalized Diluted EPS | 61.80% | -28.23% | 32.41% | 71.18% | -15.18% |
| Average Basic Shares Outstanding | 26.53% | 29.67% | 30.48% | 27.46% | 14.74% |
| Average Diluted Shares Outstanding | 26.53% | 29.67% | 30.48% | 27.46% | 14.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |